Pediatric psoriasis is a multisystem disease with significant physical, emotional, and social impacts, particularly in moderate to severe cases. Comorbidities such as depression, anxiety, obesity, and ...

Please provide your email address to receive an email when new articles are posted on . PASI and static Physician Global Assessment scores significantly improved in pediatric patients with psoriasis ...

Otezla (apremilast) is an oral tablet commonly used to treat plaque psoriasis in adults and children. Plaque psoriasis is an inflammatory skin condition that causes itchy, painful patches on the skin.

Please provide your email address to receive an email when new articles are posted on . Otezla is now available in the U.S. to treat children and adolescents with moderate to severe plaque psoriasis.

Credit: Arcutis Biotherapeutics. Zoryve is a once-daily, topical phosphodiesterase-4 (PDE4) inhibitor. The Food and Drug Administration (FDA) has approved Zoryve ® (roflumilast) cream 0.3% for the ...

The US FDA has approved guselkumab for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis (PsA) in children aged 6 years or older who weigh at least 40 kg, according ...

WESTLAKE VILLAGE, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful ...

WESTLAKE VILLAGE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...